Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
38,820,318
-
Share change
-
+804,826
-
Total reported value
-
$275,239,671
-
Price per share
-
$7.09
-
Number of holders
-
90
-
Value change
-
+$2,784,959
-
Number of buys
-
37
-
Number of sells
-
40
Institutional Holders of AEGLEA BIOTHERAPEUTICS INC - COM (AGLE) as of Q3 2020
As of 30 Sep 2020,
AEGLEA BIOTHERAPEUTICS INC - COM (AGLE) was held by
90 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,820,318 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, ORBIMED ADVISORS LLC, BlackRock Inc., Nantahala Capital Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Bain Capital Life Sciences Investors, LLC, VANGUARD GROUP INC, Aisling Capital Management LP, Rock Springs Capital Management LP, and MARSHALL WACE, LLP.
This page lists
90
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.